Skip to content

Estazolam

FDA-approved product (tablet, oral), marketed as Estazolam, Prosom.

Registered studies
12
Lab records
0
Pathogens at ≥40%
2 of 4

Chemical structure

Chemical structure of Estazolam
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Insomnia

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Benzodiazepine derivatives
FDA pharmacologic class
Benzodiazepine FDA label ↗
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against MRSA and M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA50.4% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli29.8% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae16.0% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis60.6% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

12registered studies name this medicine, for any condition. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-7.7 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-7.6 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-7.3 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-7.9 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Estazolam with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Compound Ciwujia Granules in the Treatment of Insomnia

    NCT07306494 · start 2026-01

    Registered record
    Registry ID
    NCT07306494
    Conditions
    Insomnia Disorder
    Interventions
    Compound Ciwujia Granules group; Estazolam; Compound Ciwujia Granules and estazolam
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Not yet recruiting
    Start
    2026-01
    Completion
    2028-06
    Enrolment
    1,200

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionInsomnia Disorder
    InterventionCompound Ciwujia Granules group; Estazolam; Compound Ciwujia Granules and estazolam
    PhasePhase 4
    Registry statusNot yet recruiting
  • Efficacy of Auricular Pressure Beans with Electroacupuncture and Estazolam Treating Insomnia Caused by Cancer

    NCT06859190 · start 2025-03-01

    Registered record
    Registry ID
    NCT06859190
    Conditions
    Cancer; Insomnia
    Interventions
    estazolam 1-2 mg; Auricular pressure bean combined with electroacupuncture
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Recruiting
    Start
    2025-03-01
    Completion
    2026-12-01
    Enrolment
    60

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCancer; Insomnia
    Interventionestazolam 1-2 mg; Auricular pressure bean combined with electroacupuncture
    PhasePhase 3
    Registry statusRecruiting
  • A Randomized Controlled Trial of Auricular Acupressure in Treating Estazolam-dependent Insomnia

    NCT06258226 · start 2024-07-01

    Registered record
    Registry ID
    NCT06258226
    Conditions
    Estazolam-dependent Insomnia
    Interventions
    Conventional dosage reduction; Auricular acupressure; Sham auricular acupressure
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Unknown
    Start
    2024-07-01
    Completion
    2025-06-30
    Enrolment
    108

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionEstazolam-dependent Insomnia
    InterventionConventional dosage reduction; Auricular acupressure; Sham auricular acupressure
    PhaseNot applicable
    Registry statusUnknown
  • "Chou's Tiaoshen" Acupoints for Short-term Insomnia.

    NCT06212934 · start 2024-03-01

    Registered record
    Registry ID
    NCT06212934
    Conditions
    Short-term Insomnia
    Interventions
    Acupuncture; Estazolam
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Unknown
    Start
    2024-03-01
    Completion
    2025-05-01
    Enrolment
    96

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionShort-term Insomnia
    InterventionAcupuncture; Estazolam
    PhaseNot applicable
    Registry statusUnknown
  • Treatment of Chronic Insomnia According to Yin Yang Theory and Its Correlation With Circadian Rhythm

    NCT05452577 · start 2021-01-22

    Registered record
    Registry ID
    NCT05452577
    Conditions
    Chronic Insomnia; Circadian Rhythm; Traditional Chinese Medicine
    Interventions
    Suanzaoren Decoction and Huanglian Wendan Decoction; Estazolam 1Mg Tab
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2021-01-22
    Completion
    2023-05-30
    Enrolment
    187

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionChronic Insomnia; Circadian Rhythm; Traditional Chinese Medicine
    InterventionSuanzaoren Decoction and Huanglian Wendan Decoction; Estazolam 1Mg Tab
    PhaseNot applicable
    Registry statusCompleted
  • Observation on the Effect of Auricular Acupoint Pressing on Insomnia and Adverse Events in MHD

    NCT03997058 · start 2019-03-01

    Registered record
    Registry ID
    NCT03997058
    Conditions
    Renal Dialysis; Sleep Initiation and Maintenance Disorders
    Interventions
    Auricular point pressure therapy; Oral estazolam medication
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Unknown
    Start
    2019-03-01
    Completion
    2021-01-01
    Enrolment
    120

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionRenal Dialysis; Sleep Initiation and Maintenance Disorders
    InterventionAuricular point pressure therapy; Oral estazolam medication
    PhasePhase 4
    Registry statusUnknown
  • Effects of Dexmedetomidine on Cognitive Outcome and Brain Injury Markers

    NCT03585452 · start 2018-08-01

    Registered record
    Registry ID
    NCT03585452
    Conditions
    Cognitive Dysfunction
    Interventions
    Dexmedetomidine Infusion; Propofol based general anesthesia
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2018-08-01
    Completion
    2019-03-31
    Enrolment
    23

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCognitive Dysfunction
    InterventionDexmedetomidine Infusion; Propofol based general anesthesia
    PhaseNot applicable
    Registry statusCompleted
  • Risk and Benefit Assessment of Hypnotic Agents for Sleep Disorders Among Elderly

    NCT02648776 · start 2016-01

    Registered record
    Registry ID
    NCT02648776
    Conditions
    Sleep Disorders
    Interventions
    Exposure to sedative-hypnotic drugs
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Unknown
    Start
    2016-01
    Completion
    2018-12
    Enrolment
    1,400

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSleep Disorders
    InterventionExposure to sedative-hypnotic drugs
    PhaseNot recorded
    Registry statusUnknown
  • Sunitinib or Cediranib for Alveolar Soft Part Sarcoma

    NCT01391962 · start 2011-07-18

    Registered record
    Registry ID
    NCT01391962
    Conditions
    Sarcoma, Alveolar Soft Part
    Interventions
    Cediranib; Sunitinib; Prochlorperazine; Promethazine; Benzodiazepine; Filgrastim; Sargramostim; Lomotil; Loperamide; Vitamin B6; Aquaphor; Acetaminophen; Levothyroxine; Warfarin
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2011-07-18
    Completion
    2026-01-16
    Enrolment
    34

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSarcoma, Alveolar Soft Part
    InterventionCediranib; Sunitinib; Prochlorperazine; Promethazine +10 more
    PhasePhase 2
    Registry statusCompleted
  • A Study to Evaluate Efficacy and Safety of Zolpidem Modified Release Formulation in Insomnia Patients

    NCT00956319 · start 2009-05

    Registered record
    Registry ID
    NCT00956319
    Conditions
    Sleep Initiation and Maintenance Disorders; Primary Insomnia
    Interventions
    Zolpidem MR; Estazolam
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2009-05
    Completion
    2010-11
    Enrolment
    42

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSleep Initiation and Maintenance Disorders; Primary Insomnia
    InterventionZolpidem MR; Estazolam
    PhasePhase 4
    Registry statusCompleted
  • Effects of Discontinuation of Benzodiazepine-derivative Hypnotics on Cognitive and Motor Functions in Elderly Persons

    NCT00707915 · start 2008-01

    Registered record
    Registry ID
    NCT00707915
    Conditions
    Adverse Effects
    Interventions
    Drug: Benzodiazepine (listed out below)
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2008-01
    Completion
    2010-07
    Enrolment
    30

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAdverse Effects
    InterventionDrug: Benzodiazepine (listed out below)
    PhasePhase 4
    Registry statusCompleted
  • Randomised, Double-blind Study to Investigate the Safety and Efficacy of Brotizolam in Insomnia Outpatients.

    NCT00347295 · start 2006-06

    Registered record
    Registry ID
    NCT00347295
    Conditions
    Sleep Initiation and Maintenance Disorders
    Interventions
    Brotizolam; Estazolam
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2006-06
    Completion
    2007-01
    Enrolment
    253

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSleep Initiation and Maintenance Disorders
    InterventionBrotizolam; Estazolam
    PhasePhase 3
    Registry statusCompleted